Curanex Pharmaceuticals Inc Common Stock

The Schall Law Firm is investigating Curanex Pharmaceuticals Inc. (NASDAQ: CURX) for potential securities law violations, alleging the company issued false or misleading statements and failed to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the investigation.

Curanex Pharmaceuticals announced significant progress on its lead asset Phyto-N, completing a pilot-scale GMP batch and dose-range finding toxicology studies with no significant adverse findings. The company maintains its target for IND submission in Q4 2026 for ulcerative colitis treatment and plans Phase 1 clinical development in Australia. Th...

Curanex Pharmaceuticals completed its initial public offering by having Dominari Securities fully exercise the over-allotment option, raising an additional $2.25 million and bringing total gross proceeds to $17.25 million through the issuance of 4,312,500 shares at $4.00 per share.

Curanex Pharmaceuticals completed its initial public offering of 3,750,000 shares at $4.00 per share, raising $15 million. The company, focused on botanical drugs for inflammatory diseases, began trading on Nasdaq under ticker CURX.